Back to Journals » Journal of Hepatocellular Carcinoma » Volume 4

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

Authors Fateen W, Khan F, O’Neill RJ, James MW, Ryder SD, Aithal GP

Received 15 June 2017

Accepted for publication 28 August 2017

Published 16 October 2017 Volume 2017:4 Pages 123—130

DOI https://doi.org/10.2147/JHC.S144068

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Ahmed O Kaseb

Waleed Fateen,1,2 Farooq Khan,1 Richard J O’Neill,3 Martin W James,1 Stephen D Ryder,1 Guruprasad P Aithal1,2

1NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, 2Nottingham Digestive Diseases Centre, University of Nottingham, 3Department of Radiology, Nottingham University Hospitals, NHS Trust, Nottingham, UK

Background:
A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare healthcare costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK.
Methods: Using a dedicated radiology database, we identified all patients who had undergone cTACE or DEB-TACE between 2006 and 2012 at a single tertiary referral center based in Nottingham. We collected clinical data, including treatment response, postprocedure complications and 30-day mortality. Costing models were constructed to present both our local hospital perspective as well as the national health service position.
Results: During our study period, 101 procedures were performed on 43 patients (76 cTACE procedures on 26 patients and 25 DEB-TACE procedures on 17 patients). Overall, 11/26 in cTACE and 5/17 in DEB-TACE group had progressive disease (p=0.52). Adverse events were seen in 6/76 cTACE compared with 7/25 DEB-TACE group (p=0.16). Based on the predetermined standard pathway there was an unadjusted average cost difference of £3770.30 (TACE =£9070.44, DEB-TACE =£5300.14) in favor of the DEB-TACE. Results from our costing models indicated a £2715.33 (95% CI £580.88–4849.77) cost difference in favor of the same procedure.
Conclusions: Even when the extra costs of DEB-TACE were considered, the overall treatment costs per patient were lower in relation to cTACE.

Keywords: hepatocellular carcinoma, transarterial chemoembolization, healthcare costs, drug-eluting beads, objective response

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Download Article [PDF]  View Full Text [HTML][Machine readable]